EVA1A: A Novel Target for Metabolic Dysfunction-Associated Steatotic Liver Disease

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a growing global health concern closely linked to rising rates of obesity, insulin resistance, and type 2 diabetes. Characterized by excessive fat accumulation in the liver, MASLD can progress to more severe conditions like steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).

The Link Between MASLD and Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is a primary liver cancer and a significant complication of advanced MASLD. Recent data indicates that up to 38% of HCC cases can be attributed to MASLD, occurring in both cirrhotic and non-cirrhotic livers ¹. The increasing prevalence of metabolic syndrome contributes to this alarming trend.

Introducing EVA1A: A Key Regulator of Hepatic Lipid Metabolism

Recent research has identified EVA1A, a tumor suppressor gene, as a crucial regulator of hepatic lipid metabolism and a potential therapeutic target for MASLD. A study published in 2025 by Yang et al. Demonstrated that EVA1A plays a critical role in modulating CD36 expression and its palmitoylation, impacting how the liver processes fats ².

How EVA1A Impacts Liver Health

• Downregulation in Liver Disease: Researchers found significantly reduced EVA1A expression in liver tissue from patients with HCC and co-existing fatty liver disease.
• Eva1a Knockout Mice: Liver-specific knockout of the Eva1a gene in mice led to marked hepatic steatosis and disrupted fat metabolism, establishing a direct causal link between EVA1A deficiency and lipid dysregulation.
• Restoration Improves Steatosis: Restoring EVA1A expression in obese mice (ob/ob model) via adeno-associated virus (AAV) delivery significantly improved liver steatosis by suppressing the fatty acid transporter CD36.

The EVA1A-CD36 Axis: A Detailed Look

EVA1A regulates CD36 through two primary mechanisms:

• Transcriptional Regulation: Lower EVA1A levels activate the mTORC1-PPARγ2 signaling pathway, increasing CD36 gene transcription.
• Post-Translational Modification: Reduced EVA1A inhibits the production of APT1 (a depalmitoylation enzyme) while boosting the production of ZDHHC4/5 (palmitoyl acyltransferases). This promotes CD36 palmitoylation.

Palmitoylation alters CD36’s location within the cell. It drives CD36 to the plasma membrane, increasing fatty acid uptake, and reduces its presence on mitochondria, hindering fatty acid β-oxidation.

Implications for MASLD Treatment

The discovery of the EVA1A-CD36 axis presents a novel pathogenic mechanism for MASLD and opens avenues for potential therapeutic interventions. Targeting this pathway could offer a new approach to managing MASLD and reducing the risk of progression to HCC.

Future Directions

Further research is needed to fully elucidate the complex interplay between EVA1A, CD36, and other factors involved in MASLD pathogenesis. Investigating strategies to restore EVA1A expression or modulate CD36 activity could lead to the development of effective treatments for this increasingly prevalent liver disease.

References

1. Armandi, A., Rosso, C., Caviglia, G. P., & Bugianesi, E. (2025). An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillance. Metabolism, 162, 156080. https://www.sciencedirect.com/science/article/pii/S0026049524003081
2. Caturano, A., Erul, E., Nilo, R., Nilo, D., Russo, V., Rinaldi, L., … & Akkus, E. (2025). Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad. European Journal of Clinical Investigation, 56(1), e70132. https://pmc.ncbi.nlm.nih.gov/articles/PMC12817244/